CD19 CAR T Therapy Tested in Refractory Rheumatoid Arthritis
Disease activity fell in all six participants in a phase I trial, with three achieving sustained drug-free remission during follow-up
Clinical Scorecard: CD19 CAR T Therapy Tested in Refractory Rheumatoid Arthritis
At a Glance
Category Detail
Condition Rheumatoid Arthritis Key Mechanisms CD19-directed CAR T cell therapy targeting B cells Target Population Patients with severe, treatment-refractory rheumatoid arthritis Care Setting Clinical trial setting
Key Highlights
Single infusion of CD19 CAR T cells reduced disease activity in all participants Median reduction of disease activity scores was 49% at week 24 Three participants maintained remission without medication for up to 52 weeks All participants experienced grade 1 or 2 cytokine release syndrome Study will proceed to randomized phase II stage comparing with rituximab Guideline-Based Recommendations
Diagnosis
Assessment of disease activity in rheumatoid arthritis Management
Consideration of CD19 CAR T therapy in treatment-refractory cases Monitoring & Follow-up
Monitoring for cytokine release syndrome and cytopenias post-infusion Risks
Potential for cytokine release syndrome and cytopenias Patient & Prescribing Data
Adults aged 31-69 with longstanding seropositive rheumatoid arthritis
Prior treatment with multiple disease-modifying therapies
Clinical Best Practices
Conduct thorough pre-treatment assessment for eligibility Monitor patients closely for adverse effects post-infusion Consider long-term follow-up to assess treatment effects on immunity Related Resources & Content
